{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:29:20Z","timestamp":1789082960579,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA076292"],"award-info":[{"award-number":["P30CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA244328-01"],"award-info":[{"award-number":["R01CA244328-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ymthe.2025.04.019","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T19:00:27Z","timestamp":1745002827000},"page":"3576-3589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Abraham-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Menges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald M.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Cuadrado Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Ribickas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Savid-Frontera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"de Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Castaneda Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ochoa-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.04.019_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.019_bib2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.019_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2025.04.019_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.019_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.019_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02153","article-title":"Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells","volume":"11","author":"Cooke","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.04.019_bib10","first-page":"405.e1","article-title":"Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation","volume":"27","author":"Liang","year":"2021","journal-title":"Transpl. Cell. Ther."},{"key":"10.1016\/j.ymthe.2025.04.019_bib11","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib12","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/10428194.2020.1751840","article-title":"Low absolute CD4(+) T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma","volume":"61","author":"Gu","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ymthe.2025.04.019_bib13","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/10428194.2020.1779261","article-title":"Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield","volume":"61","author":"Manasanch","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ymthe.2025.04.019_bib14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41590-021-00975-5","article-title":"Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation","volume":"22","author":"Abdel-Hakeem","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.04.019_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib17","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2023-188577","article-title":"Evaluation of the T-Cell Metabolic State of Starting Material and Manufactured CAR T Cell Products and Clinical Outcome of CAR T-Cell Therapy for Large B Cell Lymphoma","volume":"142","author":"Jacobs","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","article-title":"Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy","volume":"23","author":"Sukumar","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2025.04.019_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41422-020-0379-5","article-title":"Metabolic signaling in T cells","volume":"30","author":"Shyer","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2025.04.019_bib20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/nprot.2012.048","article-title":"Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells","volume":"7","author":"Zhang","year":"2012","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2025.04.019_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.04.019_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.202","article-title":"Mitochondrial complex II is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival","volume":"6","author":"Pfleger","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.04.019_bib24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.04.019_bib25","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2023-187663","article-title":"CAR T Cell Exhaustion but Not Ex Vivo Cytotoxicity Is Predictive of Patient Clinical Response: An Interim Analysis of ACIT001\/EXC002, a Phase Ib\/II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed\/Refractory Aggressive NHL and ALL","volume":"142","author":"Yin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/1541-7786.MCR-21-0711","article-title":"Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors","volume":"20","author":"Luo","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.04.019_bib27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.019_bib28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.04.019_bib29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib30","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.019_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.omtm.2022.06.010","article-title":"T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells","volume":"26","author":"Battram","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.019_bib33","doi-asserted-by":"crossref","first-page":"OF6","DOI":"10.1158\/2159-8290.CD-ND2023-0009","article-title":"CAR T-cell Availability for Multiple Myeloma Improving but Still Limited","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.04.019_bib34","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1200\/JCO.2022.40.16_suppl.8021","article-title":"Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy","volume":"40","author":"Rytlewski","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib35","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.019_bib36","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23561","article-title":"Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients >=60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma","volume":"88","author":"Micallef","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.019_bib38","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.4049\/jimmunol.1301148","article-title":"Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF","volume":"191","author":"Lundqvist","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.04.019_bib39","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2002-04-1200","article-title":"G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases","volume":"102","author":"Franzke","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2018.10.004","article-title":"Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion","volume":"25","author":"K\u00fcnkele","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2025.04.019_bib41","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.019_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2024-197929","article-title":"Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed\/Refractory Multiple Myeloma","volume":"144","author":"Hansen","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib43","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.04.019_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib45","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib46","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2021-145097","article-title":"Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib48","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","article-title":"DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine\/CARTITUDE-6)","volume":"140","author":"Boccadoro","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.04.019_bib49","series-title":"International Myeloma Society Annual Meeting","article-title":"Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update","author":"Mateos","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.019_bib50","series-title":"FACT-JACIE International Standards for HEMATOPOIETIC CELLULAR THERAPY-Product Collection, Processing, and Administration","author":"Moehring","year":"2021"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500293X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500293X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:43:59Z","timestamp":1786023839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162500293X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S152500162500293X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}